JNJ (Johnson & Johnson) Other Current Payables: $0 Mil (As of Mar. 2026)


JNJ Johnson & Johnson JNJ
81 GF Score
Price $261.80
GF Value $191.03
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Other Current Payables?

Johnson & Johnson JNJ -0.61% 81 Other Current Payables is $0 Mil as of Mar. 2026. GuruFocus rates JNJ with a GF Score™ of 81/100 and a GF Value™ of $191.03 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Johnson & Johnson's Other Current Payables for the quarter that ended in Mar. 2026 was $0 Mil.

Johnson & Johnson Other Current Payables Related Terms

Johnson & Johnson Other Current Payables Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Other Current Payables Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Johnson & Johnson Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
JNJ
81GF Score
Johnson & Johnson JNJ
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Johnson & Johnson Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0 Mil mean?
Johnson & Johnson (JNJ) has a Other Current Payables of $0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Johnson & Johnson and its competitors.
Is Johnson & Johnson's Other Current Payables too high?
Johnson & Johnson's current Other Current Payables is $0 Mil. Overall, Johnson & Johnson has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Other Current Payables compare to ABBV and MRK?
Johnson & Johnson's Other Current Payables of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Johnson & Johnson and its competitors. Johnson & Johnson's current Other Current Payables is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is $191.03, compared to a current price of $261.80 — trading 37% above its estimated fair value. The current Other Current Payables is $0 Mil. Johnson & Johnson's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Johnson & Johnson (JNJ), the current Other Current Payables is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson & Johnson (JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of $261.80 is trading 37% above its estimated GF Value™ of $191.03. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for JNJ:

  • Other Current Payables: $0 Mil
  • GF Value™: $191.03 vs. price of $261.80 (37% above fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
81GF Score

Get the complete analysis for JNJ

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$261.80
Price
$191.03
GF Value